A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK0941 After Multiple Daily Administration in Subjects With Type 2 Diabetes

A study to test the pharmacokinetics after twice daily administration of MK-0941 or placebo in subjects with type 2 diabetes who have inadequate control on metformin.

Inclusion Criteria:

• Subject has a BMI < 42 kg/m2
• Subject is taking >1500 mg metformin per day for at least 8 weeks
• Subject has HbA1c value of 7.0% and < 11% at screening
• Subject is willing to follow AHA weight maintaining diet and exercise program
• Subject is a nonsmoker for at least 6 months

Exclusion Criteria:

• Subject has type 1 diabetes
• Subject has a history of stroke or chronic seizure
• Subject has a history of neoplastic disease
• Subject has a history of gastrointestinal, cardiovascular, blood, liver kidney, respiratory, immunological or genitourinary disorders or diseases
• Subject is currently taking 2 or more diabetes medications
• Subject has glaucoma or is blind
• If female, subject is pregnant or breastfeeding
• Subject consumes > 3 alcoholic beverages per day
• Subject has had major surgery or has donated blood in the last 4 weeks